Linkedin Youtube Instagram Twitter Facebook
Linkedin Youtube Instagram Twitter Facebook

Mindset Pharma is a leader in developing next-generation psychedelic medicines to treat neurological and psychiatric disorders.

Download the presentation
Download
ABOUT US

Company Overview

Mindset Pharma is a Toronto-based drug discovery business focused on creating novel and patentable psychedelic compounds for the treatment of neurological and psychiatric disorders.

Play Video

Pipeline

Mindset has developed 4 families of novel, next-generation psychedelics with differentiated characteristics and improved safety profiles. Read More

Pipeline

Click to enlarge

Family

Family 1 / MSP-1014: Psilocybin-like conjugate.

Family 2: High-potency, short-acting, psilocybin-like.

Family 3: Low-potency, long-duration for micro-dosing

Family 4: DMT/ 5-MeO-DMT-inspired compounds

Lead Identification

Lead Optimization

IND-Enabling

Clinical
Phase 1

Recent News

Mar 14, 2023
Mindset Pharma To Defend Against Lawsuit Filed By Reunion Neurosciences
Read more
Read more
Mar 06, 2023
Mindset Pharma and PharmAla Complete First Sale of Pharmaceutical Grade Psilocybin Into Growing Australian Market via Sales Partnership
Read more
Read more
Feb 02, 2023
Mindset Pharma Receives Another Allowance from USPTO for Patent Application Expanding Composition of Matter for Family 1 Psilocybin Analogs
Read more
Read more
Jan 20, 2023
Mindset Pharma Receives Allowance for U.S. Patent Application Covering Composition of Matter for Its Lead Psychedelic Therapeutic Candidate, MSP-1014, And Additional Family 1 Tryptamine Prodrug Candidates
Read more
Read more
SEE ALL
NEWS
"Psychedelic medications have the potential to revolutionize the way we treat mental health"
James LanthierCEO
James Lanthier
"There is a tremendous opportunity in psychedelics to design safer and more efficacious next-generation medicines"
Joseph AraujoChief Scientific Officer
Joseph Araujo
“The psychedelic medicine space is an IP race and Mindset is in a leadership position”
Malik SlassiSenior VP, Innovation
Malik Slassi
Previous
Next
"Psychedelic medications have the potential to revolutionize the way we treat mental health"
James LanthierCEO
James Lanthier
"There is a tremendous opportunity in psychedelics to design safer and more efficacious next-generation medicines"
Joseph AraujoChief Scientific Officer
Joseph Araujo
“The psychedelic medicine space is an IP race and Mindset is in a leadership position”
Malik SlassiSenior VP, Innovation
Malik Slassi
Meet the team
Meet the team
Get to know us
Let Us Help You
Join the Conversation
Linkedin Youtube Instagram Twitter Facebook
Subscribe
Get Updates
Copyright © 2023 Mindset Pharma All rights reserved. | Disclaimer & Privacy Policy
Subscribe for latest news